Valuation & Market

Investors eye Darling's Q1 results on April 30 for a rebound in renewable fuel profits and continued strength in its core circular economy segments.

Following a period of historic earnings, the Hudson Valley bank plans to repurchase 400,000 shares, a move signaling deep confidence to investors.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

As AI risks grow, TrendLife launches Kaleida, an AI companion built to protect families, manage digital life, and restore trust in the connected home.

ASIC reports a smaller loss but slumping revenue as it sells key NYC properties. With low cash and NYSE warnings, is this a survival plan or a fire sale?

A new alliance between NASRC and ASHRAE aims to overcome key barriers to sustainable cooling by boosting research, standards, and workforce training.

The food giant's $250M bond repurchase offer was nearly doubly oversubscribed, a strong market endorsement of its financial health and strategic debt management.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

The diagnostics firm posts strong 2025 growth, but the impending loss of a key partner puts its high-stakes strategic pivot squarely to the test.

As Black Diamond readies its Q1 2026 report, investors eye gains from a booming energy market and the strategic expansion of its LodgeLink platform.

As Brookfield Residential preps its Q1 2026 earnings, all eyes are on what its results will signal for the broader North American real estate market.

Optro's inaugural EMEA conference signals a major push into Europe's complex GRC market, focusing on AI governance and transforming risk into opportunity.

Following a massive stock surge, Forte Biosciences is raising $150M. The funds are crucial for a pivotal year of clinical trials for its autoimmune drug.

Galloway Capital Partners takes a 5.44% stake in Chegg, arguing the ed-tech firm is undervalued and a strategic split could revive its fortunes.

The e-commerce giant's major vet clinic acquisition accelerates its plan to create an all-in-one ecosystem for pet parents, challenging industry titans.

A new ACORD study reveals a seismic shift in insurance M&A. The old 'bigger is better' approach now destroys value, while strategic deals thrive.

The extended partnership solidifies the two giants' grip on the VR market, promising new tools for developers and accelerating VR's push beyond gaming.

The testing giant acquires a mission-critical specialist, diving into the booming data center and semiconductor markets fueled by artificial intelligence.

For decades, toxic chemicals were the norm in HVACR. See how one family business's commitment to safety led to explosive growth and industry-wide change.